Inspire Medical Systems experienced a sharp slowdown in revenue caused by temporary disruptions in CPT coding and CMS Project WISeR, rather than fundamental business problems. The company maintains a strong balance sheet with about $400 million in liquidity and no debt, providing financial stability and supporting a valuation of 1x EV/sales despite depressed stock prices. Competitive pressures from Nyxoah and GLP-1 therapies are manageable, with Inspire's intellectual property wins and the potential market expansion from GLP-1 therapies offering growth opportunities. An investment strategy involving cash-secured puts at a $25 strike aims for over 19% annualized returns while maintaining a significant price cushion.
ISS A/S announced ongoing transactions under its share buyback programme, repurchasing a total of 3,184,170 shares at an average price of DKK 240.09, totaling approximately DKK 764.5 million. The buyback aims to reduce share capital and fulfill oblig...
United Airlines CEO Scott Kirby stated the company is open to acquiring airport slots, gates, and other strategic assets from struggling competitors. Despite a rejected merger proposal with American Airlines earlier this year, Kirby emphasized United...
Royal Unibrew initiated a share buy-back program in February 2026, which was increased from DKK 400 million to DKK 700 million in April 2026. The program is set to run until August 14, 2026, with total repurchases not exceeding DKK 700 million. As of...
Bavarian Nordic A/S has repurchased 50,169 of its own shares at an average price of DKK 182.35 since starting its share buyback program on June 2, 2026. The program allows the company to buy back shares up to a total value of DKK 150 million by July ...
Bavarian Nordic A/S has repurchased 50,169 shares at an average price of DKK 182.35, totaling DKK 9.15 million, as part of its share buy-back program running from June 2 to July 10, 2026. This program allows the company to buy back shares up to DKK 1...
